Current Report Filing (8-k)
26 3월 2019 - 12:56AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 25, 2019 (March 25, 2019)
CALMARE THERAPEUTICS INCORPORATED
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-08696
|
|
36-2664428
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of Incorporation)
|
|
|
|
Identification Number)
|
|
|
1375 Kings Highway East
|
|
|
|
|
Fairfield, CT 06824
|
|
|
|
|
(Address of principal executive offices)
|
|
|
|
|
203-368-6044
|
|
|
|
|
(Registrant’s Telephone Number)
|
|
|
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On March 25, 2019, the Registrant issued a press
release titled “Calmare Therapeutics Receives Two Favorable Rulings In Delaware Chancery Court.” A copy of the press
release is provided in this Form 8-K as Exhibit 99.1.
The information in Item 8.01 of this Form 8-K is
being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
or otherwise subject to the liabilities of that section. The information in Item 8.01 of this Form 8-K also shall not be deemed
to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of
1934, except to the extent that the Company specifically incorporates it by reference.
|
ITEM 9.01.
|
Financial Statements and Exhibits
|
Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
March 25, 2019
|
By:
|
/s/ Conrad Mir
|
|
|
|
Conrad Mir
|
|
|
Chief Executive Officer
|
Calmare Therapeutics (CE) (USOTC:CTTC)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Calmare Therapeutics (CE) (USOTC:CTTC)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Calmare Therapeutics Inc (CE) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Calmare Therapeutics Inc News Articles